Patents by Inventor Marcel B. Bally
Marcel B. Bally has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100041152Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.Type: ApplicationFiled: March 16, 2009Publication date: February 18, 2010Applicants: TEKMIRA PHARMACEUTICALS CORPORATION, THE UNIVERSITY OF BRITISH COLUMBIAInventors: Jeffery J. Wheeler, Michael J. Hope, Pieter R. Cullis, Marcel B. Bally
-
Patent number: 7422902Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.Type: GrantFiled: November 1, 1999Date of Patent: September 9, 2008Assignee: The University of British ColumbiaInventors: Jeffery J. Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope, Pieter R. Cullis, Peter Scherrer
-
Patent number: 6858224Abstract: Particle aggregation of lipid:nucleic acid complex particles is prevented by incorporating a non-cationic lipid into lipid:nucleic acid complex particles containing a cationic lipid and a nucleic acid polymer. The non-cationic lipid is a polyethylene glycol-based polymer.Type: GrantFiled: June 5, 2001Date of Patent: February 22, 2005Assignee: Inex Pharmaceuticals CorporationInventors: Jeffrey Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope
-
Patent number: 6815432Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.Type: GrantFiled: February 24, 2003Date of Patent: November 9, 2004Assignee: Inex Pharmaceuticals Corp.Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
-
Publication number: 20030181410Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.Type: ApplicationFiled: February 24, 2003Publication date: September 25, 2003Applicant: Inex Pharmaceuticals Corp.Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
-
Publication number: 20030147944Abstract: The liposomes of the invention have a reactive surface that demonstrates reduced interaction with macromolecules and increased blood circulation time. The reactive surface may comprise phosphatidylserine. The liposomes are protected by the presence of high levels of a hydrophilic polymer conjugated to a lipid. The invention further provides means for adjusting the appropriate ratio of hydrophilic polymer to a reactive lipid by a) determining the reactivity of the lipid; b) determining the time required for the carrier to reach its desired target location; c) determining the affinity of desired interactions with the reactive surface; and d) incorporating in the liposome or lipid carrier the amount of polyethylene glycol required to protect the reactive surface.Type: ApplicationFiled: November 4, 2002Publication date: August 7, 2003Inventors: Lawrence D Mayer, Gigi Chiu, Marcel B Bally
-
Patent number: 6586410Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.Type: GrantFiled: May 8, 2000Date of Patent: July 1, 2003Assignee: Inex Pharmaceuticals CorporationInventors: Jeffery J. Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope, Pieter R. Cullis, Peter Scherrer
-
Patent number: 6534484Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.Type: GrantFiled: November 8, 1999Date of Patent: March 18, 2003Assignee: Inex Pharmaceuticals Corp.Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
-
Publication number: 20020192651Abstract: Particle aggregation of lipid:nucleic acid complex particles is prevented by incorporating a non-cationic lipid into lipid:nucleic acid complex particles containing a cationic lipid and a nucleic acid polymer. The non-cationic lipid is a polyethylene glycol-based polymer.Type: ApplicationFiled: June 5, 2001Publication date: December 19, 2002Inventors: Jeffrey Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope
-
Patent number: 6083530Abstract: A method for encapsulation of antineoplastic agents in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes may be made by a process that loads the drug by an active mechanism using a transmembrane ion gradient, preferably a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%, and liposomes may be loaded with drug immediately prior to use, eliminating stability problems related to drug retention in the liposomes. Drug:lipid ratios employed are about 3-80 fold higher than for traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. An assay method to determine free antineoplastic agents in a liposome preparation is also disclosed.Type: GrantFiled: May 26, 1998Date of Patent: July 4, 2000Assignee: The Liposome Company, Inc.Inventors: Lawrence D. Mayer, Marcel B. Bally, Pieter R. Cullis, Richard S. Ginsberg, George N. Mitilenes
-
Patent number: 5981501Abstract: Plasmid-lipid particles which are useful for transfection of cells in vitro or in vivo are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. The particles are typically 65-85 nm, fully encapsulate the plasmid and are serum-stable.Type: GrantFiled: June 7, 1995Date of Patent: November 9, 1999Assignee: Inex Pharmaceuticals Corp.Inventors: Jeffery J. Wheeler, Michael Hope, Pieter R. Cullis, Marcel B. Bally
-
Patent number: 5976567Abstract: Novel lipid-nucleic acid particulate complexes which are useful for in vitro or in vivo gene transfer are described. The particles can be formed using either detergent dialysis methods or methods which utilize organic solvents. Upon removal of a solubilizing component (i.e., detergent or an organic solvent) the lipid-nucleic acid complexes form particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.Type: GrantFiled: June 6, 1996Date of Patent: November 2, 1999Assignee: Inex Pharmaceuticals Corp.Inventors: Jeffery J. Wheeler, Marcel B. Bally, Yuan-Peng Zhang, Dorothy L. Reimer, Michael Hope, Pieter R. Cullis, Peter Scherrer
-
Patent number: 5965542Abstract: Methods of forming cationic liposome/nucleic acid complexes in which the complexes have a mean diameter of about 200 to about 300 nm are provided. The complexes are formed by combining a first solution of preformed cationic unilamellar liposomes with a mean diameter of from 100 to 150 nm, with a second solution of nucleic acid. Each of the solutions are equilibrated prior to mixing to temperatures of from 0.degree. C. to about 12.degree. C., preferably about 2.degree. C. to about 7.degree. C. The preformed cationic liposomes are typically prepared from an unsaturated cationic lipid, for example DODAC, DOTAP, DOTMA, DODAP, DMRIE, DORI, DOSPA and combinations thereof, and a neutral lipid, for example DOPE or cholesterol. The combination of the first and second solutions is typically carried out by gentle mixing over ice for a period of time of from about 10 to about 60 minutes.Type: GrantFiled: March 18, 1997Date of Patent: October 12, 1999Assignee: Inex Pharmaceuticals Corp.Inventors: Ellen K. Wasan, Marcel B. Bally, Michael J. Hope, Dorothy L. Reimer, Quet Fah Ahkong
-
Patent number: 5922350Abstract: Dehydrated liposomes are prepared by drying liposome preparations under reduced pressure in the presence of one or more protective sugars, e.g., the disaccharides trehalose and sucrose. Preferably, the protective sugars are present at both the inside and outside surfaces of the liposome membranes. Freezing of the liposome preparation prior to dehydration is optional. Alternatively, the protective sugar can be omitted if: (1) the liposomes are of the type which have multiple lipid layers; (2) the dehydration is done without prior freezing; and (3) the dehydration is performed to an end point which results in sufficient water being left in the preparation (e.g., at least 12 moles water/mole lipid) so that the integrity of a substantial portion of the multiple lipid layers is retained upon rehydration.Type: GrantFiled: June 16, 1997Date of Patent: July 13, 1999Assignee: The Liposome Company, Inc.Inventors: Andrew S. Janoff, Pieter R. Cullis, Marcel B. Bally, Michael W. Fountain, Richard S. Ginsberg, Michael J. Hope, Thomas D. Madden, Hugh P. Schieren, Regina L. Jablonski
-
Patent number: 5858397Abstract: Compositions and methods which are useful for the treatment of solid tumors in a host and which are also useful for increasing the therapeutic index of mitoxantrone in a host. The pharmaceutical compositions are liposomal formulations of mitoxantrone in which the liposomes comprise a mixture of cholesterol and a diacylphosphatidylcholine, preferably 1,2-sn-dimyristoyl-phosphatidylcholine.Type: GrantFiled: October 11, 1995Date of Patent: January 12, 1999Assignee: University of British ColumbiaInventors: Howard J. Lim, Thomas D. Madden, Marcel B. Bally, Lana W. Barber, Charmaine W. Chang
-
Patent number: 5837279Abstract: Dehydrated liposomes are prepared by drying liposome preparations under reduced pressure in the presence of one or more protective sugars, e.g., the disaccharides trehalose and sucrose. Preferably, the protective sugars are present at both the inside and outside surfaces of the liposome membranes. Freezing of the liposome preparation prior to dehydration is optional. Alternatively, the protective sugar can be omitted if: (1) the liposomes are of the type which have multiple lipid layers; (2) the dehydration is done without prior freezing; and (3) the dehydration is performed to an end point which results in sufficient water being left in the preparation (e.g., at least 12 moles water/mole lipid) so that the integrity of a substantial portion of the multiple lipid layers is retained upon rehydration.Type: GrantFiled: May 25, 1995Date of Patent: November 17, 1998Assignee: The Lipsome Company, Inc.Inventors: Andrew S. Janoff, Pieter R. Cullis, Marcel B. Bally, Michael W. Fountain, Richard S. Ginsberg, Michael J. Hope, Thomas D. Madden, Hugh P. Schieren, Regina L. Jablonski
-
Patent number: 5814335Abstract: Liposomal formulations having extended circulation time in vivo and increased drug retention are comprised of sphingomyelin and cholesterol and have an acidic intraliposomal pH. The formulations have enhanced stability and thus are used in methods which provide improved drug delivery and more effective treatment. The delivery of ciprofloxacin, and alkaloid drugs, particularly swainsonine, vincristine and vinblastine, is significantly improved.Type: GrantFiled: September 17, 1997Date of Patent: September 29, 1998Assignee: Inex Pharmaceuticals CorporationInventors: Murray S. Webb, Marcel B. Bally, Lawrence D. Mayer, James J. Miller, Paul G. Tardi
-
Patent number: 5795589Abstract: A method for encapsulation of antineoplastic agents in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes may be made by a process that loads the drug by an active mechanism using a transmembrane ion gradient, preferably a tranamembrane pH gradient. Using this technique, trapping efficiencies approach 100%, and liposomes may be loaded with drug immediately prior to use, eliminating stability problem related to drug retention in the liposomes. Drug:lipid ratios employed are about 3-80 fold higher than for traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. An assay method to determine free antineoplastic agents in a liposome preparation is also disclosed.Type: GrantFiled: February 5, 1997Date of Patent: August 18, 1998Assignee: The Liposome Company, Inc.Inventors: Lawrence D. Mayer, Marcel B. Bally, Pieter R. Cullis, Richard S. Ginsberg, George N. Mitilenes
-
Patent number: 5780054Abstract: Methods of increasing the circulation half-life of protein-based therapeutics in a host, the methods comprising: (a) administering to the host an amount of a first liposome formulation comprising liposomes and an antineoplastic agent; and (b) administering to the host a second formulation comprising the protein-based therapeutic, wherein the amount of the first liposome formulation is sufficient to suppress an immune response to the protein-based therapeutic of the second formulation, thereby increasing the circulation half-life of the protein-based therapeutic.Type: GrantFiled: January 17, 1996Date of Patent: July 14, 1998Assignee: University of British ColumbiaInventors: Paul G. Tardi, Erik Swartz, Marcel B. Bally, Pieter R. Cullis
-
Patent number: 5744158Abstract: A method for encapsulation of antineoplastic agents in liposomes is provided, having preferably a high drug:lipid ratio. Liposomes may be made by a process that loads the drug by an active mechanism using a transmembrane ion gradient, preferably a transmembrane pH gradient. Using this technique, trapping efficiencies approach 100%, and liposomes may be loaded with drug immediately prior to use, eliminating stability problems related to drug retention in the liposomes. Drug:lipid ratios employed are about 3-80 fold higher than for traditional liposome preparations, and the release rate of the drug from the liposomes is reduced. An assay method to determine free antineoplastic agents in a liposome preparation is also disclosed.Type: GrantFiled: May 25, 1995Date of Patent: April 28, 1998Assignee: The Liposome Company, Inc.Inventors: Lawrence D. Mayer, Marcel B. Bally, Pieter R. Cullis, Richard S. Ginsberg, George N. Mitilenes